Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Heliox sobre el trabajo respiratorio en pacientes adultos con estenosis de las vías respiratorias inferiores

18 de septiembre de 2026 actualizado por: Marta Corral Blanco, Hospital Universitario 12 de Octubre

El efecto del heliox sobre el trabajo respiratorio en pacientes adultos con estenosis de las vías respiratorias inferiores

Heliox (a mixture of Helium and Oxygen) can reduce the work of breathing in patients with airway stenosis by modifying turbulent flow into laminar flow. The aim of this study was to analyze the effect of Heliox versus conventional oxygen therapy in patients with lower airway stenosis on muscular effort measured by electromyography and diaphragmatic ultrasound, thoracoabdominal synchrony assessed with plethysmographic bands, dyspnea, stridor, oxygen saturation, transcutaneous carbon dioxide value, blood pressure, heart rate and respiratory rate.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

Lower airway stenosis results in increased work of breathing with stridor and dyspnea, as a consequence of the increased resistances caused by the reduction in airway diameter. Airway resistance also depends on the length of the airway and the type of gas flow. Heliox (a mixture of Helium and Oxygen) is a gas less dense than air, which can change the flow from turbulent to laminar, reducing airway resistance by 20 to 40%, and therefore decreasing the work of breathing. Heliox is an inert gas that does not react with biological membranes, so there are few complications associated with its use, the most relevant being hypoxemia when fixed mixtures are not used and the the fraction of inspired oxygen (FiO2) supplied is less than 21%. The aim of the study was to evaluate if during the perioperative period of lower airway stenosis the administration of Heliox compared to oxygen could reduce the work of breathing and improve dyspnea. For this purpose, patients were treated for 30 minutes with Heliox (fixed mixture of 70% helium and 30% oxygen) using a non rebreather mask or reservoir bag versus 30 minutes with oxygen 31% using a Venturi mask.

Tipo de estudio

De observación

Inscripción (Actual)

18

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Madrid
      • Madrid, Madrid, España, 28041
        • Marta Corral Blanco

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients will be recluted from the pneumology outpatient clinic of the Hospital 12 de Octubre

Descripción

Inclusion Criteria:

  • Patients with lower airway stenosis evaluated at the Respiratory Endoscopy Unit of the Hospital Universitario 12 de Octubre on the waiting list for endoscopic intervention on stenosis.
  • Stenosis grade ≥ 3 and Borg scale score > 2.

Exclusion Criteria:

  • Presence of relevant comorbidities (uncontrolled ischemic heart disease, ventricular dysfunction, pneumopathies with severe respiratory insufficiency, severe pulmonary hypertension).
  • Inability to perform the test due to severe dyspnea or need for emergency intervention.
  • Patient on continuous mechanical ventilation, invasive or non-invasive.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Airway Stenosis

Patients with lower airway stenosis on waiting list for endoscopic intervention on stenosis by respiratory endoscopy unit.

Treatment for 30 minutes with Heliox from a commercial tank (Oxhelⓒ, Air Liquideⓒ) with a fixed mixture of 70% helium and 30% oxygen with non-rebreather mask or reservoir bag at a flow of 12-15 lpm.

Otros nombres:
  • Helio - Oxígeno

Treatment for 30 minutes with oxygen at FiO2 of 31% with Venturi mask.

Otros nombres:
  • Oxígeno 31%

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Changes in Neural Ventilatory Drive (%):
Periodo de tiempo: 30 minutes with Heliox and 30 minutes with Oxygen 31%

Percentage over the Root Mean Square peak for parasternal electromyography (EMG): averaged of the square root of the peak value and the area under the curve of parasternal EMG (%RootMeanSquare) adjusted for respiratory frequency, as a surrogate of diaphragmatic EMG, and sternocleidomastoid EMG, which will give us information on accessory muscle activation.

30 minutes with Heliox and 30 minutes with Oxygen 31%

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Diaphragmatic excursion assessed with ultrasound
Periodo de tiempo: At minute 15 during the Heliox test and at minute 15 during the Oxygen 31% test.

Assessment of muscular effort by measuring the diaphragmatic excursion (mm) at tidal volume and at vital capacity.

At minute 15 during the Heliox test and at minute 15 during the Oxygen 31% test.
Thickening fraction of the diaphragm assessed by ultrasound
Periodo de tiempo: At minute 15 during the Heliox test and at minute 15 during the Oxygen 31% test.

Assessment of muscular effort by measuring the thickening fraction of the diaphragm in the apposition zone (%).

At minute 15 during the Heliox test and at minute 15 during the Oxygen 31% test.
Changes in thoracoabdominal synchrony
Periodo de tiempo: Phase angle was calculated from 10 consecutive breaths at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.

Assessment of thoracoabdominal synchrony using thoracic and abdominal belts by calculating the phase angle with the Lissajoux loop method (plotting abdominal motion on the x-axis against thoracic motion on the y-axis).

Phase angle was calculated from 10 consecutive breaths at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
Borg Scale Dyspnea evolution (points)
Periodo de tiempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.

Degree of dyspnea will be determined by this validated scale with a result between 1 and 10 points.0: Not at all 0.5: Very, very light (hardly noticeable) 1: Very light, 2: Light, 3: Moderate , 4: Somewhat intense, 5: Intense, 6: Between 5 and 7, 7: Very intense, 8: Between 7 and 9, 9: Very, very intense (almost maximum ), 10: Maximum

Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
Oxygen saturation
Periodo de tiempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.

Measured by pulse-oximetry

Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
Transcutaneous partial pressure of carbon dioxide
Periodo de tiempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.

Transcutaneous monitor uses a noninvasive technique to measure the skin-surface partial pressure of carbon dioxide (PtcCO2)

Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
Blood pressure
Periodo de tiempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.

Non-invasive measurement with a sphygmomanometer

Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
Heart rate
Periodo de tiempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.

number of beats per minute

Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.
Respiratory rate
Periodo de tiempo: Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.

Number of breaths per minute

Basal value and at minutes 1, 5, 15 and 30 during the Heliox test and the Oxygen 31% test.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Marta Corral Blanco, MD, Hospital 12 de Octubre

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de abril de 2022

Finalización primaria (Actual)

31 de mayo de 2023

Finalización del estudio (Actual)

10 de enero de 2026

Fechas de registro del estudio

Enviado por primera vez

30 de mayo de 2024

Primero enviado que cumplió con los criterios de control de calidad

7 de junio de 2024

Publicado por primera vez (Actual)

13 de junio de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir